Healthcare provider profile · identity verified

Gurjit Kaur, DO

Internal Medicine · HOUSTON, TX · NPI 1619933827

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	479	164
Levothyroxine Sodium	Levothyroxine Sodium	364	104
Rosuvastatin Calcium	Rosuvastatin Calcium	354	114
Losartan Potassium	Losartan Potassium	342	109
Amlodipine Besylate	Amlodipine Besylate	293	96
Lisinopril	Lisinopril	207	70
Simvastatin	Simvastatin	191	60
Metformin Hcl	Metformin Hcl	167	57
Fluticasone Propionate	Fluticasone Propionate	154	58
Gabapentin	Gabapentin	139	50
Pravastatin Sodium	Pravastatin Sodium	137	45
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	134	42
Sertraline Hcl	Sertraline Hcl	132	55
Hydrochlorothiazide	Hydrochlorothiazide	111	40
Metformin Hcl Er	Metformin Hcl	96	28
Metoprolol Tartrate	Metoprolol Tartrate	95	32
Omeprazole	Omeprazole	90	34
Trazodone Hcl	Trazodone Hcl	79	22
Metoprolol Succinate	Metoprolol Succinate	75	27
Pantoprazole Sodium	Pantoprazole Sodium	67	27
Ropinirole Hcl	Ropinirole Hcl	67	17
Glipizide	Glipizide	64	20
Escitalopram Oxalate	Escitalopram Oxalate	61	23
Tizanidine Hcl	Tizanidine Hcl	59	25
Potassium Chloride	Potassium Chloride	58	19
Allopurinol	Allopurinol	55	18
Cefdinir	Cefdinir	52	47
Albuterol Sulfate Hfa	Albuterol Sulfate	49	19
Alprazolam	Alprazolam	49	13
Atenolol	Atenolol	47	16
Clopidogrel	Clopidogrel Bisulfate	47	16
Alendronate Sodium	Alendronate Sodium	46	14
Carvedilol	Carvedilol	46	18
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	45	45
Glipizide Er	Glipizide	43	17
Furosemide	Furosemide	42	15
Oxybutynin Chloride Er	Oxybutynin Chloride	42	15
Montelukast Sodium	Montelukast Sodium	41	15
Tramadol Hcl	Tramadol Hcl	41	suppressed
Buspirone Hcl	Buspirone Hcl	39	suppressed
Glimepiride	Glimepiride	39	12
Citalopram Hbr	Citalopram Hydrobromide	36	11
Ezetimibe	Ezetimibe	35	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	35	13
Tamsulosin Hcl	Tamsulosin Hcl	33	11
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	32	32
Mounjaro	Tirzepatide	31	suppressed
Fenofibrate	Fenofibrate	30	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	30	suppressed
Duloxetine Hcl	Duloxetine Hcl	29	12
Jantoven	Warfarin Sodium	29	suppressed
Bupropion Xl	Bupropion Hcl	26	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	26	suppressed
Warfarin Sodium	Warfarin Sodium	26	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	23	suppressed
Benazepril Hcl	Benazepril Hcl	23	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	23	22
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	23	17
Nifedipine Er	Nifedipine	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	19
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Azelastine Hcl	Azelastine Hcl	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Irbesartan	Irbesartan	18	suppressed
Rybelsus	Semaglutide	18	suppressed
Fenofibrate	Fenofibrate,micronized	17	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Ozempic	Semaglutide	14	suppressed
Famotidine	Famotidine	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Eliquis	Apixaban	12	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	12	suppressed
Amoxicillin	Amoxicillin	11	11
Chlorthalidone	Chlorthalidone	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error